CF
NPCE icon

Corebridge Financial’s Neuropace NPCE Stock Holding History

Corebridge Financial’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,949
Closed -$85.4K – 1819
2025
Q1 		$85.4K Buy
6,949
+50
+0.7% +$626 ﹤0.01% 2519
2024
Q4 		$77.2K Sell
6,899
-399
-5% -$3.47K ﹤0.01% 2672
2024
Q3 		$50.9K Sell
7,298
-45
-0.6% -$329 ﹤0.01% 2866
2024
Q2 		$55.6K Buy
+7,343
New +$74.1K ﹤0.01% 2873

Other funds holding NPCE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return

Corebridge Financial's NPCE Position: Q2 2025 in Review

Corebridge Financial sold out of Neuropace (NPCE) in Q2 2025, closing a stake of 6,949 shares — an estimated $85.4K sold.

Corebridge Financial first reported a position in NPCE in Q2 2024 and held it in 4 quarters. The position peaked at $85.4K in Q1 2025. 98 funds tracked by Wall St. Rank hold NPCE as of Q2 2025.

  • Corebridge Financial reported no remaining Neuropace position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 6,949 Neuropace shares in Q2 2025, an estimated $85.4K.
  • Corebridge Financial first reported a position in Neuropace in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Neuropace position peaked at $85.4K in Q1 2025.
  • 98 funds tracked by Wall St. Rank held Neuropace as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.